# Evaluation of the Safety and Efficacy of LB-DTK-BKV in Patients With BK Virus-Associated Hemorrhagic Cystitis Following Allogeneic Hematopoietic Stem Cell Transplantation

> **NCT07638332** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **LucasBio** · enrollment: 42 (estimated)

## Conditions studied

- Hemorrhagic Cystitis

## Interventions

- **BIOLOGICAL:** LB-DTK-BKV
- **OTHER:** Standard-of-care

## Key facts

- **NCT ID:** NCT07638332
- **Lead sponsor:** LucasBio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2028-03-01
- **Final completion:** 2028-03-01
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07638332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07638332, "Evaluation of the Safety and Efficacy of LB-DTK-BKV in Patients With BK Virus-Associated Hemorrhagic Cystitis Following Allogeneic Hematopoietic Stem Cell Transplantation". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07638332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*